<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38028898</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2732-494X</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>1</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Antimicrobial stewardship &amp; healthcare epidemiology : ASHE</Title><ISOAbbreviation>Antimicrob Steward Healthc Epidemiol</ISOAbbreviation></Journal><ArticleTitle>The effectiveness of COVID-19 vaccine in the prevention of post-COVID conditions: a systematic literature review and meta-analysis of the latest research.</ArticleTitle><Pagination><StartPage>e168</StartPage><MedlinePgn>e168</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e168</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1017/ash.2023.447</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">We performed a systematic literature review and meta-analysis on the effectiveness of coronavirus disease 2019 (COVID-19) vaccination against post-COVID conditions (long COVID) among fully vaccinated individuals.</AbstractText><AbstractText Label="DESIGN" NlmCategory="UNASSIGNED">Systematic literature review/meta-analysis.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We searched PubMed, Cumulative Index to Nursing and Allied Health, EMBASE, Cochrane Central Register of Controlled Trials, Scopus, and Web of Science from December 1, 2019, to June 2, 2023, for studies evaluating the COVID-19 vaccine effectiveness (VE) against post-COVID conditions among fully vaccinated individuals who received two doses of COVID-19 vaccine. A post-COVID condition was defined as any symptom that was present four or more weeks after COVID-19 infection. We calculated the pooled diagnostic odds ratio (DOR) (95% confidence interval) for post-COVID conditions between fully vaccinated and unvaccinated individuals. Vaccine effectiveness was estimated as 100% x (1-DOR).</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Thirty-two studies with 775,931 individuals evaluated the effect of vaccination on post-COVID conditions, of which, twenty-four studies were included in the meta-analysis. The pooled DOR for post-COVID conditions among fully vaccinated individuals was 0.680 (95% CI: 0.523-0.885) with an estimated VE of 32.0% (11.5%-47.7%). Vaccine effectiveness was 36.9% (23.1%-48.2%) among those who received two doses of COVID-19 vaccine before COVID-19 infection and 68.7% (64.7%-72.2%) among those who received three doses before COVID-19 infection. The stratified analysis demonstrated no protection against post-COVID conditions among those who received COVID-19 vaccination after COVID-19 infection.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Receiving a complete COVID-19 vaccination prior to contracting the virus resulted in a significant reduction in post-COVID conditions throughout the study period, including during the Omicron era. Vaccine effectiveness demonstrated an increase when supplementary doses were administered.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marra</LastName><ForeName>Alexandre R</ForeName><Initials>AR</Initials><Identifier Source="ORCID">0000-0002-7577-7688</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculdade Israelita de Ci&#xea;ncias da Sa&#xfa;de Albert Einstein, Hospital Israelita Albert Einstein, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Access &amp; Delivery Research &amp; Evaluation (CADRE), Iowa City Veterans Affairs Health Care System, Iowa City, IA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kobayashi</LastName><ForeName>Takaaki</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-4751-6859</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Callado</LastName><ForeName>Gustavo Yano</ForeName><Initials>GY</Initials><Identifier Source="ORCID">0000-0001-6694-6569</Identifier><AffiliationInfo><Affiliation>Faculdade Israelita de Ci&#xea;ncias da Sa&#xfa;de Albert Einstein, Hospital Israelita Albert Einstein, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pardo</LastName><ForeName>Isabele</ForeName><Initials>I</Initials><Identifier Source="ORCID">0009-0004-6375-4640</Identifier><AffiliationInfo><Affiliation>Faculdade Israelita de Ci&#xea;ncias da Sa&#xfa;de Albert Einstein, Hospital Israelita Albert Einstein, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gutfreund</LastName><ForeName>Maria Celidonio</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Faculdade Israelita de Ci&#xea;ncias da Sa&#xfa;de Albert Einstein, Hospital Israelita Albert Einstein, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Mariana Kim</ForeName><Initials>MK</Initials><Identifier Source="ORCID">0000-0001-8709-5484</Identifier><AffiliationInfo><Affiliation>Faculdade Israelita de Ci&#xea;ncias da Sa&#xfa;de Albert Einstein, Hospital Israelita Albert Einstein, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Vivian</ForeName><Initials>V</Initials><Identifier Source="ORCID">0009-0009-2415-5799</Identifier><AffiliationInfo><Affiliation>Faculdade Israelita de Ci&#xea;ncias da Sa&#xfa;de Albert Einstein, Hospital Israelita Albert Einstein, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alsuhaibani</LastName><ForeName>Mohammed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, King Faisal Specialist Hospital &amp; Research Centre, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasegawa</LastName><ForeName>Shinya</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7167-270X</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tholany</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-4415-4573</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perencevich</LastName><ForeName>Eli N</ForeName><Initials>EN</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Access &amp; Delivery Research &amp; Evaluation (CADRE), Iowa City Veterans Affairs Health Care System, Iowa City, IA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salinas</LastName><ForeName>Jorge L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edmond</LastName><ForeName>Michael B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>West Virginia University School of Medicine, Morgantown, WV, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rizzo</LastName><ForeName>Luiz Vicente</ForeName><Initials>LV</Initials><AffiliationInfo><Affiliation>Faculdade Israelita de Ci&#xea;ncias da Sa&#xfa;de Albert Einstein, Hospital Israelita Albert Einstein, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Antimicrob Steward Healthc Epidemiol</MedlineTA><NlmUniqueID>9918266096106676</NlmUniqueID><ISSNLinking>2732-494X</ISSNLinking></MedlineJournalInfo><CoiStatement>All authors report no conflict of interest relevant to this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>18</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>17</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>10</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38028898</ArticleId><ArticleId IdType="pmc">PMC10644173</ArticleId><ArticleId IdType="doi">10.1017/ash.2023.447</ArticleId><ArticleId IdType="pii">S2732494X23004473</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sharif N, Alzahrani KJ, Ahmed SN, Dey SK. Efficacy, immunogenicity and safety of COVID-19 vaccines: a systematic review and meta-analysis. Front Immunol 2021;12:714170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8542872</ArticleId><ArticleId IdType="pubmed">34707602</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. Int J Infect Dis: Off Publ Int Soc Infect Dis 2022;114:252&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8595975</ArticleId><ArticleId IdType="pubmed">34800687</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde MW, Self WH, Adams K, et al. Association between mRNA vaccination and COVID-19 hospitalization and disease severity. JAMA 2021;326:2043&#x2013;2054.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8569602</ArticleId><ArticleId IdType="pubmed">34734975</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammed I, Nauman A, Paul P, et al. The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review. Human Vaccines Immunother 2022;18:2027160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8862168</ArticleId><ArticleId IdType="pubmed">35113777</ArticleId></ArticleIdList></Reference><Reference><Citation>Chenchula S, Karunakaran P, Sharma S, Chavan M. Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: a systematic review. J Med Virol 2022;94:2969&#x2013;2976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9088621</ArticleId><ArticleId IdType="pubmed">35246846</ArticleId></ArticleIdList></Reference><Reference><Citation>Regev-Yochay G, Gonen T, Gilboa M, et al. Efficacy of a fourth dose of Covid-19 mRNA vaccine against Omicron. N Engl J Med 2022;386:1377&#x2013;1380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9006792</ArticleId><ArticleId IdType="pubmed">35297591</ArticleId></ArticleIdList></Reference><Reference><Citation>
Centers for Disease Control and Prevention (CDC). National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases, 2022. Long COVID or post-COVID conditions. https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html. Accessed 20 May, 2022.</Citation></Reference><Reference><Citation>
Centers for Disease Control and Prevention, 2023. Post-COVID conditions. https://data.cdc.gov/NCHS/Post-COVID-Conditions/gsea-w83j. Accessed 8 June, 2023.</Citation></Reference><Reference><Citation>Marra AR, Kobayashi T, Suzuki H, et al. The effectiveness of coronavirus disease 2019 (COVID-19) vaccine in the prevention of post-COVID-19 conditions: a systematic literature review and meta-analysis. Antimicrob Stewardship Healthc Epidemiol 2022;2:e192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9726631</ArticleId><ArticleId IdType="pubmed">36505947</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold DT, Milne A, Samms E, Stadon L, Maskell NA, Hamilton FW. Symptoms after COVID-19 vaccination in patients with persistent symptoms after acute infection: a case series. Ann Int Med 2021;174:1334&#x2013;1336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8252827</ArticleId><ArticleId IdType="pubmed">34029484</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatesan P. Do vaccines protect from long COVID? Lancet Resp Med 2022;10:e30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8776281</ArticleId><ArticleId IdType="pubmed">35065716</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2707599</ArticleId><ArticleId IdType="pubmed">19621072</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 2000;283:2008&#x2013;2012.</Citation><ArticleIdList><ArticleId IdType="pubmed">10789670</ArticleId></ArticleIdList></Reference><Reference><Citation>Emecen AN, Keskin S, Turunc O, et al. The presence of symptoms within 6 months after COVID-19: a single-center longitudinal study. Irish J Med Sci 2023;192:741&#x2013;750.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9205653</ArticleId><ArticleId IdType="pubmed">35715663</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;ndez-Aceituno A, Garc&#xed;a-Hern&#xe1;ndez A, Larumbe-Zabala E. COVID-19 long-term sequelae: Omicron versus Alpha and Delta variants. Infect Dis Now 2023;53:104688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9970656</ArticleId><ArticleId IdType="pubmed">36858287</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Maaden T, Mutubuki EN, de Bruijn S, et al. Prevalence and severity of symptoms 3 months after infection with SARS-CoV-2 compared to test-negative and population controls in the Netherlands. J Infect Dis 2023;227:1059&#x2013;1067.</Citation><ArticleIdList><ArticleId IdType="pubmed">36477364</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahlert CR, Strahm C, G&#xfc;sewell S, et al. Post-acute sequelae after SARS-CoV-2 infection by viral variant and vaccination status: a multicenter cross-sectional study. Clin Infect Dis Off Publ Infect Dis Soc Am 2023;77:194&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10371307</ArticleId><ArticleId IdType="pubmed">36905145</ArticleId></ArticleIdList></Reference><Reference><Citation>Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Commun Health 1998;52:377&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1756728</ArticleId><ArticleId IdType="pubmed">9764259</ArticleId></ArticleIdList></Reference><Reference><Citation>Alderson PGS HJ, editors. Assessment of Study Quality. Cochrane Reviewer&#x2019;s Handbook 4.2.3 [Updated November 2004]. Chichester, UK: John Wiley &amp; Sons, Ltd; 2004.</Citation></Reference><Reference><Citation>
Doebler P, Holling H
, Sousa-Pinto B. Meta-analysis of diagnostic accuracy with mada. R Project Organization website. https://cran.r-project.org/web/packages/mada/vignettes/mada.pdf. Published 2017. Accessed October 4, 2023.</Citation></Reference><Reference><Citation>Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005;58:982&#x2013;990.</Citation><ArticleIdList><ArticleId IdType="pubmed">16168343</ArticleId></ArticleIdList></Reference><Reference><Citation>Goto M, Ohl ME, Schweizer ML, Perencevich EN. Accuracy of administrative code data for the surveillance of healthcare-associated infections: a systematic review and meta-analysis. Clin Infect Dis Off Publ Infect Dis Soc Am 2014;58:688&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pubmed">24218103</ArticleId></ArticleIdList></Reference><Reference><Citation>Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw 2010;36:1&#x2013;48.</Citation></Reference><Reference><Citation>Alghamdi HY, Alrashed AM, Jawhari AM, Abdel-Moneim AS. Neuropsychiatric symptoms in post-COVID-19 long haulers. Acta Neuropsychiatr 2022;34:318&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">35543105</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nature Med 2022;28:1461&#x2013;1467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis 2022;22:43&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8409907</ArticleId><ArticleId IdType="pubmed">34480857</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet (Lond Engl) 2022;399:2263&#x2013;2264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Arjun MC, Singh AK, Pal D, et al. Characteristics and predictors of Long COVID among diagnosed cases of COVID-19. PloS One 2022;17:e0278825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9767341</ArticleId><ArticleId IdType="pubmed">36538532</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, Bosworth ML, King S, et al. Risk of long COVID in people infected with severe acute respiratory syndrome Coronavirus 2 after 2 doses of a coronavirus disease 2019 vaccine: community-based, matched cohort study. Open Forum Infect Dis 2022;9:ofac464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9494414</ArticleId><ArticleId IdType="pubmed">36168555</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzolini E, Levi R, Sarti R, et al. Association between BNT162b2 vaccination and long COVID after infections not requiring hospitalization in health care workers. JAMA 2022;328:676&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9250078</ArticleId><ArticleId IdType="pubmed">35796131</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballouz T, Menges D, Kaufmann M, et al. Post COVID-19 condition after Wildtype, Delta, and Omicron SARS-CoV-2 infection and prior vaccination: pooled analysis of two population-based cohorts. PloS One 2023;18:e0281429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9946205</ArticleId><ArticleId IdType="pubmed">36812215</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunvoll SH, Nygaard AB, Fagerland MW, et al. Post-acute symptoms 3-15 months after COVID-19 among unvaccinated and vaccinated individuals with a breakthrough infection. Int J Infect Dis Off Publ Int Soc Infect Dis 2023;126:10&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9651990</ArticleId><ArticleId IdType="pubmed">36375693</ArticleId></ArticleIdList></Reference><Reference><Citation>El Otmani H, Nabili S, Berrada M, Bellakhdar S, El Moutawakil B, Abdoh Rafai M. Prevalence, characteristics and risk factors in a Moroccan cohort of Long-Covid-19. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol 2022;43:5175&#x2013;5180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9132567</ArticleId><ArticleId IdType="pubmed">35614173</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajjaji N, Lepoutre K, Lakhdar S, et al. 16 months follow up of patients&#x2019; behavior and mild COVID-19 patterns in a large cohort of cancer patients during the pandemic. Front Oncol 2022;12:901426.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9209649</ArticleId><ArticleId IdType="pubmed">35747798</ArticleId></ArticleIdList></Reference><Reference><Citation>Hastie CE, Lowe DJ, McAuley A, et al. Outcomes among confirmed cases and a matched comparison group in the Long-COVID in Scotland study. Nature Commun 2022;13:5663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9556711</ArticleId><ArticleId IdType="pubmed">36224173</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannou GN, Baraff A, Fox A, et al. Rates and factors associated with documentation of diagnostic codes for long COVID in the National Veterans Affairs Health Care System. JAMA Netw Open 2022;5:e2224359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9338411</ArticleId><ArticleId IdType="pubmed">35904783</ArticleId></ArticleIdList></Reference><Reference><Citation>Jassat W, Mudara C, Vika C, et al. A cohort study of post-COVID-19 condition across the Beta, Delta, and Omicron waves in South Africa: 6-month follow-up of hospitalized and nonhospitalized participants. Int J Infect Dis Off Publ Int Soc Infect Dis 2023;128:102&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9800016</ArticleId><ArticleId IdType="pubmed">36587841</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuodi P, Gorelik Y, Zayyad H, et al. Association between BNT162b2 vaccination and reported incidence of post-COVID-19 symptoms: cross-sectional study 2020-21, Israel. NPJ Vaccines 2022;7:101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9411827</ArticleId><ArticleId IdType="pubmed">36028498</ArticleId></ArticleIdList></Reference><Reference><Citation>Marra AR, Sampaio VS, Ozahata MC, et al. Risk factors for long coronavirus disease 2019 (long COVID) among healthcare personnel, Brazil, 2020-2022. Infect Contr Hosp Epidemiol 2023:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10755155</ArticleId><ArticleId IdType="pubmed">37272468</ArticleId></ArticleIdList></Reference><Reference><Citation>Meza-Torres B, Delanerolle G, Okusi C, et al. Differences in clinical presentation with long COVID after community and hospital infection and associations with all-cause mortality: English sentinel network database study. JMIR Publ Health Surveill 2022;8:e37668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9384859</ArticleId><ArticleId IdType="pubmed">35605170</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohr NM, Plumb ID, Harland KK, et al. Presence of symptoms 6 weeks after COVID-19 among vaccinated and unvaccinated US healthcare personnel: a prospective cohort study. BMJ Open 2023;13:e063141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9895915</ArticleId><ArticleId IdType="pubmed">36731936</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehme M, Braillard O, Chappuis F, et al. One-year persistent symptoms and functional impairment in SARS-CoV-2 positive and negative individuals. J Int Med 2022;292:103&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9115262</ArticleId><ArticleId IdType="pubmed">35555926</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlis RH, Santillana M, Ognyanova K, et al. Prevalence and correlates of long COVID symptoms among US adults. JAMA Netw Open 2022;5:e2238804&#x2013;e2238804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9614581</ArticleId><ArticleId IdType="pubmed">36301542</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinato DJ, Ferrante D, Aguilar-Company J, et al. Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer. Eur J Cancer (Oxford Engl 1990) 2022;171:64&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9124924</ArticleId><ArticleId IdType="pubmed">35704976</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard SA, Pollett SD, Fries AC, et al. Persistent COVID-19 symptoms at 6 months after onset and the role of vaccination before or after SARS-CoV-2 infection. JAMA Netw Open 2023;6:e2251360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9857077</ArticleId><ArticleId IdType="pubmed">36652247</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvaskandan H, Nimmo A, Savino M, et al. Burnout and long COVID among the UK nephrology workforce: results from a national survey investigating the impact of COVID-19 on working lives. Clin Kidney J 2022;15:517&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8754810</ArticleId><ArticleId IdType="pubmed">35198158</ArticleId></ArticleIdList></Reference><Reference><Citation>Senjam SS, Balhara YPS, Kumar P, et al. A comprehensive assessment of self-reported post COVID-19 symptoms among beneficiaries of hospital employee scheme at a tertiary healthcare institution in Northern India. Int J Gen Med 2022;15:7355&#x2013;7372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9509009</ArticleId><ArticleId IdType="pubmed">36164285</ArticleId></ArticleIdList></Reference><Reference><Citation>Tannous J, Pan AP, Potter T, et al. Real-world effectiveness of COVID-19 vaccines and anti-SARS-CoV-2 monoclonal antibodies against postacute sequelae of SARS-CoV-2: analysis of a COVID-19 observational registry for a diverse US metropolitan population. BMJ Open 2023;13:e067611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10083521</ArticleId><ArticleId IdType="pubmed">37019490</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Dercon Q, Harrison PJ. Six-month sequelae of post-vaccination SARS-CoV-2 infection: a retrospective cohort study of 10,024 breakthrough infections. Brain Behav Immun 2022;103:154&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9013695</ArticleId><ArticleId IdType="pubmed">35447302</ArticleId></ArticleIdList></Reference><Reference><Citation>Thaweethai T, Jolley SE, Karlson EW, et al. Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA 2023;329:1934&#x2013;1946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10214179</ArticleId><ArticleId IdType="pubmed">37278994</ArticleId></ArticleIdList></Reference><Reference><Citation>Zisis SN, Durieux JC, Mouchati C, Perez JA, McComsey GA. The protective effect of coronavirus disease 2019 (COVID-19) vaccination on postacute sequelae of COVID-19: a multicenter study from a large national health research network. Open Forum Infect Dis 2022;9:ofac228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9129153</ArticleId><ArticleId IdType="pubmed">35818362</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Li X, Gu X, et al. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir Med 2022;10:863&#x2013;876.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9094732</ArticleId><ArticleId IdType="pubmed">35568052</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D, Sun A, Ssentongo AE, et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open 2021;4:e2128568&#x2013;e2128568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlis RH, Santillana M, Ognyanova K, et al. Prevalence and correlates of long COVID symptoms among US adults. JAMA Netw Open 2022;5:e2238804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9614581</ArticleId><ArticleId IdType="pubmed">36301542</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C, Cancela-Cilleruelo I, Rodr&#xed;guez-Jim&#xe9;nez J, et al. Associated-onset symptoms and post-COVID-19 symptoms in hospitalized COVID-19 survivors infected with Wuhan, Alpha or Delta SARS-CoV-2 variant. Pathogens 2022;11:725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9320021</ArticleId><ArticleId IdType="pubmed">35889971</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaichana U, Man KKC, Chen A, et al. Definition of post-COVID-19 condition among published research studies. JAMA Netw Open 2023;6:e235856.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10077105</ArticleId><ArticleId IdType="pubmed">37017970</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post Coronavirus Disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review. J Infect Dis 2022;226:1593&#x2013;1607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organization, 2021. Coronavirus disease (COVID-19): post COVID-19 condition. https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-post-covid-19-condition. Accessed 21 May, 2022.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>